Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases [Yahoo! Finance]
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Yahoo! Finance
Sangamo Therapeutics and Astellas have entered into a license agreement that grants Astellas exclusive rights to use Sangamo's novel adeno-associated virus (AAV) capsid, STAC-BBB, to deliver genomic medicines for certain neurological diseases. Astellas will pay Sangamo a $20 million upfront fee and up to $1.3 billion in additional fees and milestone payments, as well as royalties on potential sales. Sangamo's STAC-BBB capsid has shown potent blood-brain barrier penetration and neuronal transduction in nonhuman primates, and the agreement aims to advance treatments for neurological diseases with significant unmet medical needs. Generated by Yahoo Finance AI Yahoo Finance used generative AI to summarize key information from this article. Some details may be inaccurate. We take that seriously. Reporting mistakes helps us improve these summaries. Was this helpful? Yes No Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five po
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- Sangamo Therapeutics, Inc. (SGMO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their RightsAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMOAccesswire
- SGMO ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Sangamo Therapeutics, Inc. investmentAccesswire
- Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to ConnectAccesswire
- SGMO ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Sangamo Therapeutics, Inc. Shareholders Who Lost MoneyAccesswire
SGMO
Earnings
- 11/12/24 - Beat
SGMO
Sec Filings
- 12/30/24 - Form 8-K
- 12/10/24 - Form 8-K
- 11/26/24 - Form 4
- SGMO's page on the SEC website